BioSpace News Archive

Business

IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results

IMV Inc. today announced alongside the release of its fourth quarter and annual results that it has engaged Stonegate Healthcare Partners, L.L.C (“Stonegate”) to explore strategic alternatives following a review of its business.

March 16, 2023
·
14 min read
NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test

NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR assay, a liquid biopsy test for molecular/minimal residual disease (MRD).

March 16, 2023
·
5 min read
Drug Development

AmplifyBio Emerges as a Leader in Cell Therapy Characterization, Filling a Gap in Pre-Clinical Development

AmplifyBio builds on the T-cell immunology expertise of its South San Francisco-based team, adding technology platforms and capabilities in single-cell analysis and product assessment in the context of a tumor microenvironment.

March 16, 2023
·
3 min read
Business

MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update

MediWound Ltd. (NASDAQ: MDWD), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the fourth quarter and the year ended December 31, 2022 and provided a corporate update.

March 16, 2023
·
18 min read
Business

Zephyr AI and KangarooHealth Announce Partnership to Harness the Power of Remote Patient Monitoring and Artificial Intelligence

Zephyr AI, Inc. (“Zephyr AI”) and KangarooHealth, Inc. (“KangarooHealth”) announced today a multi-year strategic partnership to work toward providing clinicians with insights to inform treatment decisions for patients diagnosed with chronic conditions.

March 16, 2023
·
4 min read
Drug Development

Alterity Therapeutics Enrolls First Patient in the U.S. in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics today announced the first participant has been dosed in the U.S. in the Company’s Phase 2 clinical trial of ATH434 in Multiple System Atrophy (MSA), a rare and highly debilitating Parkinsonian disorder.

March 16, 2023
·
6 min read
Bulletin from the extraordinary general meeting in Immunovia AB

On 16th March 2023, an extraordinary general meeting was held in Immunovia AB, 556730-4299 at The Spark, Scheeletorget 1, Medicon Village, in Lund.

March 16, 2023
·
3 min read
Drug Development

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

Arbutus Biopharma Corporation today announced that the first subject has been dosed in the Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of AB-161.

March 16, 2023
·
6 min read
Business

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Century Therapeutics, Inc. today reported financial results and business highlights for the full-year ended December 31, 2022.

March 16, 2023
·
9 min read
Business

Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 ResultsConference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET

Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 23, 2023 before the market open.

March 16, 2023
·
4 min read